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Cyclic GMP-dependent protein kinase I (PKG) is highly
expressed in smooth muscle cells (SMC) and mediates the
effects of nitric oxide (NO) on smooth muscle relaxation
and SMC-specific gene expression. To understand the
mechanisms by which PKG stimulates SMC-specific gene
expression, we examined the effects of PKG over-expres-
sion in passaged rat aortic SMC that express low levels of
PKG and SMC-specific genes. PKG enhances serum-
response factor (SRF) and myocardin (MY)- induced
reporter gene expression in SMC. These effects were not
dependent on induction of either SRF or MY. The Ternary
Complex Element transcription factor, Elk-1, is known to
inhibit SRF-MY induced SMC gene expression when phos-
phorylated in response to platelet derived growth factor
(PDGF). PKG inhibited Elk-1 repression of SRF-MY gene
transcription by stimulating post-translational modifica-
tion of phospho-Elk-1 via the small ubiquitin-like modi-
fier (SUMO). The mechanism of PKG-induced
sumoylation of Elk-1 may be dependent on the phospho-
rylation of SENP-1 (sumo-specific protease 1) at ser-125.
These results suggest that PKG regulates SRF-MY gene
expression through de-repression of Elk-1 on SMC-spe-
cific promoters.
PKG expression is highly variable in SMC and recent stud-
ies have shown that inflammatory cytokines (TNF and IL-
1) inhibit PKG mRNA and protein expression in primary
cultures of vascular SMC. In order to gain further insight
into the mechanism of PKG repression by inflammatory
mediators, we examined the role of cGMP itself in regulat-
ing PKG protein expression. Incubation of SMC with
phosphodiesterase-resistant cGMP analogs decreased
PKG-I protein levels in a ubiquitin-dependent manner.
Overexpression of soluble guanylyl cyclase alpha and beta
subunits and treatment with long-acting NO donors also
down-regulated PKG protein expression. Furthermore,
treatment of Cos7 cells with 8-Br-cGMP (which normally
do not express PKG) that over-express PKG resulted in
ubiquitination and down-regulation of PKG expression.
Inhibition of proteosome dependent proteolysis with
MG132 increased both PKG ubiquitination and PKG pro-
tein levels in Cos7 cells. Down-regulation of PKG protein
expression and ubiquitination by cGMP was also blocked
with DT-2, a PKG-I specific inhibitor, suggesting that
autophosphorylation of PKG may important in PKG
ubiquitination. These results suggest that the levels of
PKG-I in cells are carefully controlled by elevations in
cGMP and excessive cGMP production down-regulates
PKG protein expression through the ubiquitin-proteo-
some pathway. These results also provide a possible role
for autophosphorylation of PKG-I in controlling enzyme
levels.
Taken together, these studies suggest that PKG plays an
important role in regulating SMC growth and phenotype.
Signaling through the NO-cGMP pathway enhances SRF-
MY dependent gene expression that leads to increased
expression of SMC contractile proteins. A decrease in PKG
expression in SMC under normal physiological condi-
tions of inflammation may be dependent on cytokine-
induced elevation of cGMP in the cells, which leads to
proteosome dependent degradation of PKG. Down-regu-
lation of PKG expression may be an important adaptation
of SMC in response to inflammation thereby allowing
SMC to undergo phenotypic changes necessary for normal
vessel growth and repair.
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